Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats

OBJECTIVES: To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. METHODS: Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. RESULTS: Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. CONCLUSIONS: Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.